Prognostic features of recurrent midline and H3 K27M-mutant glioma

Authors

• Stephen J. Bagley, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
• Yoshie Umemura, Department of Neuro-Oncology, Barrow Neurological Institute, Phoenix, AZ 85013, USA.
• Joe S. Mendez, Department of Neurosurgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
• Isabel Arrillaga-Romany, Department of Neuro-Oncology, Massachusetts General Hospital, Boston, MA 02214, USA.
• Kevin J. Bielamowicz, Department of Pediatrics, Arkansas Children's Hospital, The University of Arkansas for Medical Sciences, Little Rock, AR 72202, USA.
• Nick Butowski, Department of Neuro-Oncology, University of California, San Francisco, CA 94143, USA.
• Kelley Hutchins, Department of Hematology/Oncology, Hawaii Pacific Health, Honolulu, HI 96813, USA.
• Xiao-Tang Kong, Department of Neurology, University of California Irvine, Irvine, CA 92697, USA.
• Yazmin Odia, Miami Cancer Institute, Miami, FL 33176, USA.
• Akanksha Sharma, Department of Neuro-Oncology, Saint John's Cancer Institute, Pacific Neuroscience Institute, Santa Monica, CA 90404, USA.
• Lauren Weintraub, Department of Pediatrics, Albany Medical Center, Albany, NY 12208, USA.
• Carl Koschmann, Department of Pediatric Neuro-Oncology, University of Michigan, Ann Arbor, MI 48109, USA.
• Patrick Y. Wen, Center for Neuro-Oncology, Dana-Farber Center Institute, Boston, MA 02215, USA.
• Amanda M. Saratsis, Advocate Health - MidwestFollow
• Tom Brundage, Chimerix Inc., A Jazz Pharmaceuticals Company, Durham, NC 27713, USA.
• Samuel C. Ramage, Chimerix Inc., A Jazz Pharmaceuticals Company, Durham, NC 27713, USA.
• Rohinton S. Tarapore, Chimerix Inc., A Jazz Pharmaceuticals Company, Durham, NC 27713, USA.
• Truman Knowles, Department of Neuro-Oncology, University of California, San Francisco, CA 94143, USA.
• Dewen Yang, Chimerix Inc., A Jazz Pharmaceuticals Company, Durham, NC 27713, USA.
• Joshua E. Allen, Chimerix Inc., A Jazz Pharmaceuticals Company, Durham, NC 27713, USA.
• Timothy Cloughesy, Department of Neurology, University of California, Los Angeles, CA 90095, USA.

Recommended Citation

Bagley SJ, Umemura Y, Mendez JS, et al. Prognostic Features of Recurrent Midline and H3 K27M-Mutant Glioma. Cancers (Basel). 2025;17(13):2107. Published 2025 Jun 23. doi:10.3390/cancers17132107

Document Type

Article

PubMed ID

40647406